Gender | Age
Item
males patients aged 18 years or over on entry into the trial
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Prostate carcinoma | First line treatment Complete
Item
patients who have non-metastatic cancer that is confirmed by histology or cytology. this primary treatment should have been completed in the last 8 weeks
boolean
C0600139 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
TNM clinical staging
Item
the stage should be t1b/t1c/t2/t3/t4 any n category
boolean
C3258246 (UMLS CUI [1])
Informed Consent
Item
paitents must have given written, fully informed consent to participate in the trial prior to any trial specific assessments being made
boolean
C0021430 (UMLS CUI [1])
Protocol Compliance
Item
be able and prepared to comply with trial procedures and restrictions
boolean
C0525058 (UMLS CUI [1])
Life Expectancy
Item
have a life expectancy greater than 2 years
boolean
C0023671 (UMLS CUI [1])
Hypersensitivity Therapeutic radiology procedure
Item
any known sensitivity to radiation therapy or any conditions which in the investigator's opinion may lead to radiation sensitivity
boolean
C0020517 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
Malignant Neoplasms | Basal cell carcinoma | Squamous cell carcinoma of skin | cancer treatment
Item
patients with any concurrent malignancy (except for basal cell or to-2 no mo squamous cell carcinoma of the skin). history of previous malignancy or treatment for any cancer in the past 5 years
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0553723 (UMLS CUI [3])
C0920425 (UMLS CUI [4])
Mastectomy | Mastectomy for gynecomastia | Therapeutic radiology procedure Chest
Item
previous history of mastectomy including a webster operation or radiation therapy to the chest area
boolean
C0024881 (UMLS CUI [1])
C0473513 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0817096 (UMLS CUI [3,2])
Male Castration | Medical Castration | Androgen Antagonists | Therapeutic procedure | Oestrogen therapy
Item
any previous treatment with surgical or medical castration, anti-androgens, monotherapy or oestrogen therapy at any time
boolean
C0007347 (UMLS CUI [1])
C1513054 (UMLS CUI [2])
C0002842 (UMLS CUI [3])
C0087111 (UMLS CUI [4])
C0279494 (UMLS CUI [5])
Gynecomastia Pre-existing Evidence of | Mastodynia Pre-existing Evidence of
Item
any evidence of pre-existing gynaecomastia or breast pain
boolean
C0018418 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C0332120 (UMLS CUI [1,3])
C0024902 (UMLS CUI [2,1])
C2347662 (UMLS CUI [2,2])
C0332120 (UMLS CUI [2,3])
Abnormality Testicular | Testicular Neoplasms Exacerbated Due to Casodex
Item
patients with history or presence of testicular abnormalities (as casodex can potentially aggravate testicular tumours)
boolean
C1704258 (UMLS CUI [1,1])
C0205070 (UMLS CUI [1,2])
C0039590 (UMLS CUI [2,1])
C1444749 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0591237 (UMLS CUI [2,4])
Comorbidity At risk Study Subject Participation Status | Condition At risk Study Subject Participation Status | Comorbidity Interferes with Protocol Compliance | Condition Interferes with Protocol Compliance | Body build Preventing Assessment Gynecomastia
Item
patients with any concurrent disease or condition that in the opinion of the treating physician, would constitute a hazard for participation in this study or may interfere with the patient's ability to comply with the scheduled visits and assessments. this includes patients whose physical build would prevent reasonable assessment of gynaecomastia
boolean
C0009488 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C0009488 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0525058 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0525058 (UMLS CUI [4,3])
C1318474 (UMLS CUI [5,1])
C1292733 (UMLS CUI [5,2])
C1516048 (UMLS CUI [5,3])
C0018418 (UMLS CUI [5,4])
Liver disease | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
liver disease (bilirubin greater than 2.0mg/dl; ast/alt greater than 2 times the upper limit or normal)
boolean
C0023895 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Pharmaceutical Preparations Drug Interactions Possible | Terfenadine | Cisapride | Astemizole | Cyclosporine | Warfarin
Item
patients taking the following drugs; terfenadine, cisapride, astemizole, cyclosporin, and warfarin are excluded from the trial due to the possibility of drug interaction
boolean
C0013227 (UMLS CUI [1,1])
C0687133 (UMLS CUI [1,2])
C0332149 (UMLS CUI [1,3])
C0085173 (UMLS CUI [2])
C0072916 (UMLS CUI [3])
C0085170 (UMLS CUI [4])
C0010592 (UMLS CUI [5])
C0043031 (UMLS CUI [6])
Alcohol abuse
Item
patients with a known history of alcohol abuse
boolean
C0085762 (UMLS CUI [1])
Pharmacotherapy Causing Gynecomastia | Pharmacotherapy Causing Mastodynia | Spironolactone | Steroid therapy | Cimetidine | Antipsychotic Agents
Item
concurrent treatment with any druges known to have high potential for causing gynaecomastia or breast pain, eg.spironolactone, steroid therapy, cimetidine and neuroleptic agents.
boolean
C0013216 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0018418 (UMLS CUI [1,3])
C0013216 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C0024902 (UMLS CUI [2,3])
C0037982 (UMLS CUI [3])
C0149783 (UMLS CUI [4])
C0008783 (UMLS CUI [5])
C0040615 (UMLS CUI [6])
Study Subject Participation Status | Investigational New Drugs
Item
treatment with a new chemical entity within the previous 4 months or current participation in another clinical trial involving an investigational product
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
disease transmission Risk | Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases | Hepatitis
Item
patients considered by the investigator to be at risk of transmitting any infection through the body or other body fluids, including acquired immue dificiency syndrome (aids) other sexually transmitted diseases or hepatitis
boolean
C0242781 (UMLS CUI [1,1])
C0035647 (UMLS CUI [1,2])
C0001175 (UMLS CUI [2])
C0036916 (UMLS CUI [3])
C0019158 (UMLS CUI [4])